Extensive dissection of non-metastatic tumor-draining lymph nodes (TDLNs-) significantly reduces progression-free survival (PFS) in patients with recurrent biliary tract cancer (BTC) receiving immunotherapy.
Non-metastatic lymph nodes serve as a critical reservoir for TCF-1+PD-1-CD8+ tumor-specific memory T cells and CD11c+ conventional dendritic cells.
Multiplex immunofluorescence (mIF) analysis indicates that TDLNs- possess a more favorable immune microenvironment compared to metastatic lymph nodes (TDLNs+), which are characterized by terminally exhausted T cells and regulatory T cells.
A selective lymphadenectomy approach that preserves TDLNs- while clearing TDLNs+ may optimize outcomes for patients undergoing postoperative immunotherapy.
Background: The Evolving Role of Lymphadenectomy in the Era of Immunotherapy
